Drug Repurposing in Oncology: How Existing Medicines Are Fighting Cancer

By Editorial Team
Cancer remains one of the most complex and challenging diseases globally, demanding innovative therapeutic strategies. One promising approach gaining momentum is drug repurposing — the use of existing, approved medications originally developed for non-cancer conditions to treat various cancers. This strategy leverages known safety profiles and pharmacology of these drugs, potentially accelerating cancer treatment development while reducing costs.

What Is Drug Repurposing?

Drug repurposing, also called drug repositioning, involves identifying new therapeutic uses for medications already approved for other diseases. Instead of developing a new drug from scratch, which can take over a decade and billions of dollars, repurposed drugs can move more quickly into clinical trials for cancer due to established safety and dosing data.

Examples of Repurposed Drugs in Cancer Therapy

Several well-known drugs have been successfully repurposed or are under active investigation for cancer treatment:

  • Thalidomide: Originally prescribed for morning sickness but withdrawn due to teratogenic effects, thalidomide was later found to have anti-angiogenic and immunomodulatory properties. It is now used to treat multiple myeloma and other blood cancers under strict regulation.

  • Metformin: A widely used anti-diabetic drug, metformin lowers insulin levels, which is significant because hyperinsulinemia can promote cancer growth. Metformin has shown potential in reducing cancer risk and improving outcomes in various cancers.

  • Itraconazole: An antifungal agent, itraconazole exhibits anti-angiogenic effects and has demonstrated activity against lung, breast, ovarian, prostate, and pancreatic cancers, either alone or combined with chemotherapy.

  • Penfluridol: An antipsychotic drug studied for its anti-cancer effects in melanoma, glioblastoma, breast, pancreatic, and lung cancers. It induces apoptosis and autophagy, reduces invasiveness by downregulating integrins, and enhances chemotherapy efficacy.

  • Clotrimazole: Another antifungal with potential to disrupt tumor cell cycles, currently being explored for anticancer properties.

These examples highlight the diverse range of drugs—from antipsychotics to antifungals and diabetes medications—that can be repurposed for oncology.

Advantages of Drug Repurposing in Oncology

  • Cost-Effectiveness: Repurposed drugs are often off-patent generics, significantly lowering treatment costs compared to novel cancer drugs.

  • Safety Profiles Established: Since these drugs are already approved for human use, their toxicity, dosing, and side effects are well documented, reducing early-stage trial risks.

  • Faster Development: The drug development timeline is shortened because preclinical safety assessments are largely complete.

  • Combination Therapy Potential: Repurposed drugs can be combined with existing chemotherapies or immunotherapies to enhance efficacy and overcome drug resistance.

Challenges and Barriers

Despite its promise, drug repurposing faces several hurdles:

  • Limited Commercial Incentives: Many repurposed drugs are generic, offering low financial returns for pharmaceutical companies, which limits investment in expensive clinical trials.

  • Scientific Validation Needed: While preclinical data are promising, robust clinical trials are essential to confirm efficacy and safety in cancer patients.

  • Bioavailability Issues: Some repurposed drugs have poor absorption or distribution in the body, requiring reformulation, such as nanoparticle delivery systems, to improve therapeutic levels.

  • Regulatory and Socio-Political Factors: Navigating regulatory approval for new indications and gaining acceptance in clinical practice can be complex.

Innovative Approaches to Accelerate Repurposing

Projects like the Repurposing Drugs in Oncology (ReDO) initiative work to identify promising candidates and facilitate their transition into clinical trials. Nanotechnology is also being explored to enhance drug delivery and overcome pharmacokinetic limitations.

Research teams worldwide are investigating repurposed drugs targeting critical cancer pathways, such as the TGF-beta signaling in lung cancer, aiming to prevent tumor growth and resistance.

The Future of Drug Repurposing in Cancer Treatment

Drug repurposing holds transformative potential to expand cancer treatment options with more affordable, safer, and effective therapies. As research advances, integrating repurposed drugs into combination regimens and personalized medicine approaches may improve patient outcomes.

However, realizing this potential requires coordinated efforts among researchers, clinicians, regulatory bodies, and funding agencies to overcome scientific, financial, and regulatory challenges.

In summary, drug repurposing is a promising frontier in oncology, turning familiar medicines into new weapons against cancer. With continued innovation and collaboration, this approach could significantly enhance cancer care accessibility and efficacy in the near future.

References:

  • AMDI Newsletter, 2022: Repurposing generic drugs for cancer treatment1

  • Nature, 2024: Drug repurposing for cancer therapy2

  • German Centre for Lung Research, 2025: Drug repurposing in lung cancer3

  • PMC, 2025: Drug repurposing for cancer treatment: current and future directions4

  • MDPI, 2023: Drug Repurposing for Cancer Treatment: A Comprehensive Review Cancer remains one of the most complex and challenging diseases globally, demanding innovative therapeutic strategies. One promising approach gaining momentum is drug repurposing — the use of existing, approved medications originally developed for non-cancer conditions to treat various cancers. This strategy leverages known safety profiles and pharmacology of these drugs, potentially accelerating cancer treatment development while reducing costs.

    What Is Drug Repurposing?

    Drug repurposing, also called drug repositioning, involves identifying new therapeutic uses for medications already approved for other diseases. Instead of developing a new drug from scratch, which can take over a decade and billions of dollars, repurposed drugs can move more quickly into clinical trials for cancer due to established safety and dosing data.

    Examples of Repurposed Drugs in Cancer Therapy

    Several well-known drugs have been successfully repurposed or are under active investigation for cancer treatment:

    • Thalidomide: Originally prescribed for morning sickness but withdrawn due to teratogenic effects, thalidomide was later found to have anti-angiogenic and immunomodulatory properties. It is now used to treat multiple myeloma and other blood cancers under strict regulation.

    • Metformin: A widely used anti-diabetic drug, metformin lowers insulin levels, which is significant because hyperinsulinemia can promote cancer growth. Metformin has shown potential in reducing cancer risk and improving outcomes in various cancers.

    • Itraconazole: An antifungal agent, itraconazole exhibits anti-angiogenic effects and has demonstrated activity against lung, breast, ovarian, prostate, and pancreatic cancers, either alone or combined with chemotherapy.

    • Penfluridol: An antipsychotic drug studied for its anti-cancer effects in melanoma, glioblastoma, breast, pancreatic, and lung cancers. It induces apoptosis and autophagy, reduces invasiveness by downregulating integrins, and enhances chemotherapy efficacy.

    • Clotrimazole: Another antifungal with potential to disrupt tumor cell cycles, currently being explored for anticancer properties.

    These examples highlight the diverse range of drugs—from antipsychotics to antifungals and diabetes medications—that can be repurposed for oncology.

    Advantages of Drug Repurposing in Oncology

    • Cost-Effectiveness: Repurposed drugs are often off-patent generics, significantly lowering treatment costs compared to novel cancer drugs.

    • Safety Profiles Established: Since these drugs are already approved for human use, their toxicity, dosing, and side effects are well documented, reducing early-stage trial risks.

    • Faster Development: The drug development timeline is shortened because preclinical safety assessments are largely complete.

    • Combination Therapy Potential: Repurposed drugs can be combined with existing chemotherapies or immunotherapies to enhance efficacy and overcome drug resistance.

    Challenges and Barriers

    Despite its promise, drug repurposing faces several hurdles:

    • Limited Commercial Incentives: Many repurposed drugs are generic, offering low financial returns for pharmaceutical companies, which limits investment in expensive clinical trials.

    • Scientific Validation Needed: While preclinical data are promising, robust clinical trials are essential to confirm efficacy and safety in cancer patients.

    • Bioavailability Issues: Some repurposed drugs have poor absorption or distribution in the body, requiring reformulation, such as nanoparticle delivery systems, to improve therapeutic levels.

    • Regulatory and Socio-Political Factors: Navigating regulatory approval for new indications and gaining acceptance in clinical practice can be complex.

    Innovative Approaches to Accelerate Repurposing

    Projects like the Repurposing Drugs in Oncology (ReDO) initiative work to identify promising candidates and facilitate their transition into clinical trials. Nanotechnology is also being explored to enhance drug delivery and overcome pharmacokinetic limitations.

    Research teams worldwide are investigating repurposed drugs targeting critical cancer pathways, such as the TGF-beta signaling in lung cancer, aiming to prevent tumor growth and resistance.

    The Future of Drug Repurposing in Cancer Treatment

    Drug repurposing holds transformative potential to expand cancer treatment options with more affordable, safer, and effective therapies. As research advances, integrating repurposed drugs into combination regimens and personalized medicine approaches may improve patient outcomes.

    However, realizing this potential requires coordinated efforts among researchers, clinicians, regulatory bodies, and funding agencies to overcome scientific, financial, and regulatory challenges.

    In summary, drug repurposing is a promising frontier in oncology, turning familiar medicines into new weapons against cancer. With continued innovation and collaboration, this approach could significantly enhance cancer care accessibility and efficacy in the near future.

    References:

    • AMDI Newsletter, 2022: Repurposing generic drugs for cancer treatment1

    • Nature, 2024: Drug repurposing for cancer therapy2

    • German Centre for Lung Research, 2025: Drug repurposing in lung cancer3

    • PMC, 2025: Drug repurposing for cancer treatment: current and future directions4

    • MDPI, 2023: Drug Repurposing for Cancer Treatment: A Comprehensive Review (5)

Comments

Post a Comment

Popular posts from this blog

Fenbendazole vs Ivermectin for Cancer: Differences and Which Is Better?

By Editorial Team
Image
Cancer patients are increasingly inquiring about the use of the anthelmintic drugs Fenbendazole (FenBen) and Ivermectin (IVM) as potential treatments for cancer. Notably, these patients typically fall into two distinct groups, neither of which represents the usual stage 1 or 2 cancer cases where conventional therapies often show promise. The first group consists of older men whose lung or prostate cancer has recurred. Having undergone conventional treatments previously without success, they express skepticism about its effectiveness this time around. The second, larger group comprises younger patients under 40 dealing with aggressive breast cancer, colorectal cancer, or lymphoma—forms of early-onset cancers that appear to lack the typical mutations observed in traditional cases. This article aims to delve into the differences between Fenbendazole and Ivermectin by examining their me...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2025)

By Editorial Team
Image
Fenbendazole and ivermectin, both antiparasitic drugs that have shown potential in cancer treatment through several mechanisms, such as slowing cancer cell growth and boosting the immune response. Fenbendazole is being studied for its ability to disrupt energy production in cancer cells, effectively hindering their growth. Ivermectin, on the other hand, has been explored in combination with checkpoint inhibitors to boost the immune system's response to tumors—especially in challenging cases like triple-negative breast cancer. Introduction Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies....
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2025)

By Editorial Team
Image
Are you overwhelmed by conflicting advice on cancer, diet, and supplements ? You’re not alone. With so many claims out there, it’s hard to separate fact from fiction . Can certain foods lower your cancer risk ? Are some foods increasing it without you realizing? What about vitamin and mineral supplements —do they help prevent cancer, or could they actually increase your risk ? The term " anti-cancer supplements " can be misleading. While some nutrients support the body in cancer prevention or treatment, others may interfere with therapies or even pose risks. This guide compiles over 500 scientific references on cancer, diet, and supplements—helping you navigate the facts with ...
Read more

Ivermectin for Cancer Treatment: Protocols and Evidence (2025 Edition)

By Editorial Team
Image
Ivermectin, a drug primarily used to treat parasitic infections, has gained attention for its potential anti-cancer properties, particularly in alternative treatment protocols. Popularized by figures like Dr. William Makis, these protocols combine ivermectin with supplements and lifestyle changes to target aggressive cancers. This article explores the science, protocols, case reports, risks, and controversies surrounding ivermectin’s use in cancer treatment, providing a balanced guide for readers. What is the Ivermectin Cancer Protocol? Ivermectin cancer protocols, notably those developed by Dr. William Makis, combine ivermectin with supplements like curcumin, vitamin D, and berberine, alongside dietary and lifestyle changes. These protocols are tailored to cancer severity, with higher doses recommended for aggressive cases. The term “turbo cancers,” used by some proponents, refers to rapidly progressing cancers, though it is not a standard medical term and lacks clear scientific defin...
Read more

Fenbendazole and Ivermectin for Cancer Case Series: Over 150 Case Reports (2025)

By Editorial Team
Image
Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. However, we acknowledge that robust clinical trials are needed to provide more conclusive scientific evidence. Table of Contents: Editor's Preface Introduction Fenbendazole and Ivermectin Case Series Compilation (alphabetical) Breast Cancer Success Storie...
Read more

Fenbendazole Dosage for Cancer in Humans: Benefits, Risks, and Guidelines (2025)

By Editorial Team
Image
What is Fenbendazole? Fenbendazole is an anthelmintic drug commonly used to treat parasitic infections in animals. However, recent research and anecdotal reports suggest it may have potential anticancer properties in humans. How Does Fenbendazole Work for Cancer? Fenbendazole is believed to work by disrupting microtubules in cancer cells, leading to cell cycle arrest and apoptosis (cell death). Some studies suggest it may also modulate glucose metabolism, limiting cancer cell energy supply. Recommended Fenbendazole Dosage for Cancer in Humans The commonly referenced Joe Tippens Protocol suggests the following dosage: Potential Side Effects of Fenbendazole in Humans While generally considered safe, potential side effects may include: Gastrointestinal discomfort (nausea, diarrhea, bloating) Liver enzyme elevation (rare) Bone marrow suppression (rare) Safety and Precautions Medical Supervision: Always consult with a doctor, especially if combining with other treatments. Drug Interaction...
Read more

Fenbendazole and the Joe Tippens Protocol: A Comprehensive Guide (2025)

By Editorial Team
Image
The Joe Tippens Cancer Protocol has gained attention as an alternative approach to cancer treatment, popularized by Joe Tippens, a cancer survivor who credits his recovery to fenbendazole, a veterinary anthelmintic, combined with supplements. This article provides a step-by-step guide to the protocol, explores its scientific basis, shares case reports, and discusses risks and controversies to help readers make informed decisions. What is the Joe Tippens Protocol? The Joe Tippens Protocol involves fenbendazole, a drug typically used to treat parasitic infections in animals, alongside supplements and lifestyle changes. The protocol aims to disrupt cancer cell growth, though it remains experimental and lacks approval for human use by regulatory bodies like the FDA. Below is a summary of the protocol’s components, as updated in 2020: Lifestyle Recommendations : Diet : Eliminate refined sugars and processed foods; focus on whole foods like vegetables, lean proteins, and healthy fats. Exerci...
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

By Editorial Team
Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

How One Cancer Survivor Triggered Interest in Repurposed Anti-Parasitic Drugs

By Editorial Team
Image
Joe Tippens never planned to discover a potential remedy that he credits with saving his life and thrust him into the spotlight among notable cancer survivors. The 67-year-old businessman told The Epoch Times he just wanted to beat a type of cancer with an extremely low survival rate. In August 2016, Tippens was diagnosed with small cell lung cancer with a fist-sized tumor. After undergoing chemotherapy and radiation five times a week in Houston, the large tumor in his left lung was eliminated. However, Tippens said the treatments came closer to killing him than curing him. When he returned home to Oklahoma after the New Year, he received devastating news. His oncologist told him he had zero chance of surviving for more than a few months. “In January of 2017, my PET scan lit up like a Christmas tree and I had wide metastasis everywhere, including in my neck, bones, pancreas, and liver,” Tippens said. Finding a Lifeline Facing a prognosis of three months to live, Tippens heard an intrig...
Read more

2025 Study: Ivermectin and Balstilimab for Stage 4 Triple Negative Breast Cancer - Cedars-Sinai Medical Center Study

By Editorial Team
Image
Authors: Yuan Yuan, Jin Sun Bitar, MaLia Walker, David Lin, January Lee, So Yung Choi, Stephen Shiao, Mourad Tighiouart, Paul H. Frankel, Peter P. Lee Affiliation: Cedars-Sinai Medical Center, Los Angeles, CA Abstract e13146  (2025 ASCO Annual Meeting) is a phase 1/2 study of ivermectin in combination with balstilimab after 1-2 prior lines of therapy for triple negative breast cancer Background: Despite recent FDA approval of immune checkpoint inhibitor (ICI) and antibody-drug conjugates (ADCs), therapeutic options for metastatic triple negative breast cancer (mTNBC) remain limited. Preclinical data showed that ivermectin induces robust T cell infiltration into breast tumors and turning “cold” tumors “hot” in mouse model of TNBC. Balstilimab is a fully humanized IgG4 anti-PD-1 agent with proven safety and efficacy in metastatic cervical cancer. The current phase I/II trial is designed to test the safety and efficacy of the combination of ivermectin and balstilimab in patients with...
Read more

Archive

Show more